Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ATT
Abattis Bioceuticals
C$0.00
C$0.05
C$0.74
N/AN/A1.42 million shsN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$28.65
+0.9%
$27.43
$23.69
$31.72
$12.55B0.68800,456 shs948,581 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ATT
Abattis Bioceuticals
0.00%0.00%0.00%0.00%0.00%
Smith & Nephew plc stock logo
SNN
Smith & Nephew
+1.02%-0.63%+7.95%+9.67%+11.78%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ATT
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
2.1873 of 5 stars
1.03.02.50.03.10.03.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ATT
Abattis Bioceuticals
0.00
N/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
2.00
Hold$28.00-2.27% Downside

Current Analyst Ratings Breakdown

Latest BRFI, SNN, BHMU, and ATT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$27.00 ➝ $28.00
4/25/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/25/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/17/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$27.00 ➝ $27.00
3/12/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
2/26/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$27.00 ➝ $27.00
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ATT
Abattis Bioceuticals
N/AN/AN/AN/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$5.81B2.16$3.58 per share8.00$11.94 per share2.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ATT
Abattis Bioceuticals
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$263M$2.1613.2614.331.26N/AN/AN/A8/5/2025 (Estimated)
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ATT
Abattis Bioceuticals
N/AN/AN/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
$0.893.11%N/A41.20%N/A

Latest BRFI, SNN, BHMU, and ATT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/26/2025
Smith & Nephew plc stock logo
SNN
Smith & Nephew
semi-annual$0.44702.5%3/28/20253/28/20255/28/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ATT
Abattis Bioceuticals
N/AN/AN/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
0.63
2.51
1.11

Institutional Ownership

CompanyInstitutional Ownership
ATT
Abattis Bioceuticals
N/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
25.64%

Insider Ownership

CompanyInsider Ownership
ATT
Abattis Bioceuticals
N/A
Smith & Nephew plc stock logo
SNN
Smith & Nephew
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
ATT
Abattis Bioceuticals
N/AN/AN/ANot Optionable
Smith & Nephew plc stock logo
SNN
Smith & Nephew
20,100437.96 million432.83 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Abattis Bioceuticals CNSX:ATT

Abattis Bioceuticals Corp. is a specialty biotechnology company. The Company aggregates, incubates, integrates and invests in the natural health product and botanical drug development industry. It operates through the segment of producing, licensing and marketing ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The Company, through its subsidiaries, develops and commercializes natural health (nutraceutical) products, and conducts research and development to create plant-based (botanical) intellectual property and ingredients for the pharmaceutical and bioceutical markets, among others. It offers products and services, such as botanical blends and formulas; cannabidiol ingredients; functional foods and beverages, and analytical services. It is focused on creating botanical formulations, medical marijuana and specialized health products for pain caused by inflammation, and mental ailments.

Smith & Nephew stock logo

Smith & Nephew NYSE:SNN

$28.65 +0.25 (+0.88%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$28.64 -0.01 (-0.05%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.